UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended			Commission File Number
~~June 30, 2023~~March 31, 2024			001-39218

CONMED CORPORATION

(Exact name of the registrant as specified in its charter)


Delaware			16-0977505
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

11311 Concept Blvd	Largo,	Florida	33773
(Address of principal executive offices)			(Zip Code)

(727) 392-6464

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.01 par value	CNMD	NYSE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act (Check one).

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐

Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The number of shares outstanding of registrant's common stock, as of ~~July 24, 2023~~April 22, 2024 is ~~30,739,751~~30,800,747 shares.

CONMED CORPORATION

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED ~~JUNE 30, 2023~~MARCH 31. 2024


PART I FINANCIAL INFORMATION
Item Number		Page

Item 1.	Financial Statements (unaudited)

	– Consolidated Condensed Statements of Comprehensive Income ~~(Loss)~~ for the three ~~and six~~ months ended ~~June 30~~,March 31, 2024 and 2023 ~~and 2022~~	1

	– Consolidated Condensed Balance Sheets as of ~~June 30, 2023~~March 31, 2024 and December 31, ~~2022~~2023	2

	– Consolidated Condensed Statements of Shareholders' Equity for the s ix three months ended ~~June 30~~,March 31, 2024 and 2023 ~~and 2022~~	3

	– Consolidated Condensed Statements of Cash Flows for the ~~six~~three months ended ~~June 30~~,March 31, 2024 and 2023 ~~and 2022~~	54

	– Notes to Consolidated Condensed Financial Statements	65


Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	2320

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3025

Item 4.	Controls and Procedures	3025

PART II OTHER INFORMATION

Item 1.	Legal Proceedings	3026

Item 5.	Other Information	3026

Item 6.	Exhibits	3127


Signatures		3228

Table of Contents

PART I FINANCIAL INFORMATION

Item 1.

CONMED CORPORATION

CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME ~~(LOSS)~~

(Unaudited, in thousands except per share amounts)








		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2023		2022		2023		2022
Net sales	Net sales	$	317,652	$	277,190	$	613,121	$	519,516
Net sales
Net sales

Cost of sales

Cost of sales

Cost of sales	Cost of sales	146,962		125,413		287,110		231,748

Gross profit	Gross profit	170,690		151,777		326,011		287,768

Gross profit

Gross profit

Selling and administrative expense	Selling and administrative expense	129,700		115,826		259,784		218,701

Selling and administrative expense

Selling and administrative expense

Research and development expense

Research and development expense

Research and development expense	Research and development expense	13,572		11,493		26,110		22,165

Operating expenses	Operating expenses	143,272		127,319		285,894		240,866

Operating expenses

Operating expenses

Income from operations

Income from operations

Income from operations	Income from operations	27,418		24,458		40,117		46,902

Interest expense	Interest expense	9,997		5,928		20,252		10,926

Other expense (See Note 11)		—		112,011		—		112,011
Interest expense

Income (loss) before income taxes		17,421		(93,481)		19,865		(76,035)
Interest expense

Income before income taxes

Income before income taxes

Income before income taxes

Provision for income taxes	Provision for income taxes	3,689		74,810		4,314		77,281

Net income (loss)		$	13,732	$	(168,291)	$	15,551	$	(153,316)
Provision for income taxes

Comprehensive income (loss)		$	15,767	$	(172,636)	$	20,462	$	(156,221)
Provision for income taxes

Net income

Net income

Net income

Comprehensive income

Comprehensive income

Comprehensive income

Per share data:	Per share data:

Net income (loss)

Per share data:

Per share data:

Net income

Net income

Net income
Basic	Basic	$	0.45	$	(5.65)	$	0.51	$	(5.18)
Basic
Basic
Diluted
Diluted
Diluted	Diluted	0.43		(5.65)		0.49		(5.18)

Weighted average common shares	Weighted average common shares

Weighted average common shares

Weighted average common shares
Basic
Basic
Basic	Basic	30,662		29,775		30,587		29,601
Diluted	Diluted	31,795		29,775		31,499		29,601
Diluted
Diluted

See notes to consolidated condensed financial statements.

Table of Contents

CONMED CORPORATION

CONSOLIDATED CONDENSED BALANCE SHEETS

(Unaudited, in thousands except share and per share amounts)


		June 30, 2023		December 31, 2022
	March 31, 2024						March 31, 2024	December 31, 2023
ASSETS	ASSETS					ASSETS
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	27,848	$	28,942
Accounts receivable, net	Accounts receivable, net	229,256		191,345
Inventories	Inventories	327,309		332,320
Prepaid expenses and other current assets	Prepaid expenses and other current assets	31,109		28,619
Total current assets	Total current assets	615,522		581,226
Property, plant and equipment, net	Property, plant and equipment, net	116,788		115,611
Goodwill	Goodwill	815,634		815,429
Other intangible assets, net	Other intangible assets, net	665,584		681,799
Other assets	Other assets	109,194		103,527
Total assets	Total assets	$	2,322,722	$	2,297,592

LIABILITIES AND SHAREHOLDERS' EQUITY	LIABILITIES AND SHAREHOLDERS' EQUITY

LIABILITIES AND SHAREHOLDERS' EQUITY

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:	Current liabilities:					Current liabilities:
Current portion of long-term debt	Current portion of long-term debt	$	69,632	$	69,746
Accounts payable	Accounts payable	78,577		73,393
Accrued compensation and benefits	Accrued compensation and benefits	55,052		54,733
Other current liabilities	Other current liabilities	149,908		98,680
Total current liabilities	Total current liabilities	353,169		296,552

Long-term debt	Long-term debt	971,475		985,076
Long-term debt
Long-term debt
Deferred income taxes	Deferred income taxes	66,081		66,725
Other long-term liabilities	Other long-term liabilities	151,803		203,694
Total liabilities	Total liabilities	1,542,528		1,552,047

Commitments and contingencies	Commitments and contingencies
Commitments and contingencies
Commitments and contingencies

Shareholders' equity:
Shareholders' equity:
Shareholders' equity:	Shareholders' equity:
Preferred stock, par value $0.01 per share;	Preferred stock, par value $0.01 per share;					Preferred stock, par value $0.01 per share;
authorized 500,000 shares; none outstanding	authorized 500,000 shares; none outstanding	—		—
Common stock, par value $0.01 per share; 100,000,000 shares authorized; 31,299,194 shares issued in 2023 and 2022, respectively		313		313
Common stock, par value $0.01 per share; 100,000,000 shares authorized; 31,299,194 shares issued in 2024 and 2023, respectively
Paid-in capital	Paid-in capital	432,780		413,235
Retained earnings	Retained earnings	415,924		412,631
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(52,947)		(57,858)
Less: 565,685 and 811,532 shares of common stock in treasury, at cost, in 2023 and 2022, respectively		(15,876)		(22,776)
Less: 508,028 and 534,000 shares of common stock in treasury, at cost, in 2024 and 2023, respectively
Total shareholders’ equity	Total shareholders’ equity	780,194		745,545
Total liabilities and shareholders’ equity	Total liabilities and shareholders’ equity	$	2,322,722	$	2,297,592

See notes to consolidated condensed financial statements.

Table of Contents

CONMED CORPORATION

CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY

(Unaudited, in thousands except per share amounts)


		Common Stock			Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock		Shareholders’ Equity		Common Stock		Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Shareholders’ Equity
		Shares	Amount												Shares	Amount
Balance at December 31, 2022		31,299	$	313	$	413,235	$	412,631	$	(57,858)	$	(22,776)	$	745,545
Balance at December 31, 2023
Common stock issued under employee plans	Common stock issued under employee plans				556						2,044		2,600
Stock-based compensation	Stock-based compensation				5,726								5,726
Dividends on common stock ($0.20 per share)	Dividends on common stock ($0.20 per share)						(6,113)						(6,113)

Settlement of convertible notes hedge transactions
Settlement of convertible notes hedge transactions
Settlement of convertible notes hedge transactions
Settlement of convertible notes
Comprehensive income:	Comprehensive income:
Cash flow hedging gain, net	Cash flow hedging gain, net								877
Cash flow hedging gain, net
Cash flow hedging gain, net
Pension liability, net
Pension liability, net
Pension liability, net	Pension liability, net								403
Foreign currency translation adjustments	Foreign currency translation adjustments								1,596
Foreign currency translation adjustments
Foreign currency translation adjustments
Net income
Net income
Net income	Net income						1,819
Total comprehensive income	Total comprehensive income												4,695
Total comprehensive income
Total comprehensive income

Balance at March 31, 2023		31,299	$	313	$	419,517	$	408,337	$	(54,982)	$	(20,732)	$	752,453
Common stock issued under employee plans					6,841						4,856		11,697
Stock-based compensation					6,422								6,422
Dividends on common stock ($0.20 per share)							(6,145)						(6,145)

Comprehensive income:
Cash flow hedging gain, net									503
Pension liability, net									403
Foreign currency translation adjustments									1,129
Net income							13,732
Total comprehensive income													15,767
Balance at June 30, 2023		31,299	$	313	$	432,780	$	415,924	$	(52,947)	$	(15,876)	$	780,194
Balance at March 31, 2024
Balance at March 31, 2024
Balance at March 31, 2024

~~Table of Contents~~

Common Stock Paid-in
Capital Retained
Earnings Accumulated
Other
Comprehensive
Loss Treasury
Stock Shareholders’
Equity
Shares Amount
Balance at December 31, 2021 31,299 $ 313 $ 396,771 $ 496,605 $ (54,203) $ (54,051) $ 785,435
Common stock issued under employee plans 2,232 4,020 6,252
Stock-based compensation 4,463 4,463
Dividends on common stock ($0.20 per share) (5,899) (5,899)
Comprehensive income (loss):
Cash flow hedging gain, net 1,082
Pension liability, net 521
Foreign currency translation adjustments (163)
Net income 14,975
Total comprehensive income 16,415
Cumulative effect of change in accounting principle(1)
(37,911) 20,791 (17,120)
Balance at March 31, 2022 31,299 $ 313 $ 365,555 $ 526,472 $ (52,763) $ (50,031) $ 789,546
Common stock issued under employee plans 611 633 1,244
Stock-based compensation 5,755 5,755
Dividends on common stock ($0.20 per share) (6,092) (6,092)
Shares issued for the settlement of convertible notes (25,890) 25,890 —
Convertible note premium on extinguishment 103,125 103,125
Settlement of convertible notes hedge transactions 118,912 118,912
Settlement of warrants (96,758) (96,758)
Issuance of convertible notes hedge transactions, net of tax (142,128) (142,128)
Issuance of warrants 72,000 72,000
Comprehensive income (loss):
Cash flow hedging gains, net 4,662
Pension liability, net 490
Foreign currency translation adjustments (9,497)
Net loss (168,291)
Total comprehensive loss (172,636)
Balance at June 30, 2022 31,299 $ 313 $ 401,182 $ 352,089 $ (57,108) $ (23,508) $ 672,968
(1)We recorded the cumulative impact of adopting Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity in 2022.


	Common Stock			Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock		Shareholders’ Equity
	Shares	Amount
Balance at December 31, 2022	31,299	$	313	$	413,235	$	412,631	$	(57,858)	$	(22,776)	$	745,545
Common stock issued under employee plans				556						2,044		2,600
Stock-based compensation				5,726								5,726
Dividends on common stock ($0.20 per share)						(6,113)						(6,113)
Comprehensive income:
Cash flow hedging gain, net								877
Pension liability, net								403
Foreign currency translation adjustments								1,596
Net income						1,819
Total comprehensive income												4,695

Balance at March 31, 2023	31,299	$	313	$	419,517	$	408,337	$	(54,982)	$	(20,732)	$	752,453

See notes to consolidated condensed financial statements.

Table of Contents

CONMED CORPORATION

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)


		Six Months Ended					Three Months Ended
		June 30,					March 31,
		2023		2022			2024	2023
Cash flows from operating activities:	Cash flows from operating activities:					Cash flows from operating activities:
Net income (loss)		$	15,551	$	(153,316)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Net income
Adjustments to reconcile net income to net cash provided by (used in) operating activities:						Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation	Depreciation	8,222		8,090

Amortization of deferred debt issuance costs
Amortization of deferred debt issuance costs
Amortization of deferred debt issuance costs	Amortization of deferred debt issuance costs	3,012		1,916
Amortization	Amortization	27,777		26,065
Stock-based compensation	Stock-based compensation	12,148		10,218

Deferred income taxes	Deferred income taxes	(607)		70,402
Deferred income taxes
Deferred income taxes
Non-cash adjustment to fair value of contingent consideration liability	Non-cash adjustment to fair value of contingent consideration liability	3,799		—
Loss on early extinguishment of debt		—		3,426
Loss on convertible notes conversion premium		—		103,125
Loss on convertible notes hedge transactions settlement		—		5,460

Increase (decrease) in cash flows from changes in assets and liabilities:

Increase (decrease) in cash flows from changes in assets and liabilities:

Increase (decrease) in cash flows from changes in assets and liabilities:	Increase (decrease) in cash flows from changes in assets and liabilities:
Accounts receivable	Accounts receivable	(35,184)		(17,779)
Inventories	Inventories	4,468		(35,549)
Accounts payable	Accounts payable	4,453		13,724
Accrued compensation and benefits	Accrued compensation and benefits	(253)		(12,260)
Other assets	Other assets	(11,907)		(11,388)
Other liabilities	Other liabilities	(8,653)		6,936
Net cash provided by operating activities		22,826		19,070
Net cash provided by (used in) operating activities

Cash flows from investing activities:
Cash flows from investing activities:
Cash flows from investing activities:	Cash flows from investing activities:

Purchases of property, plant and equipment	Purchases of property, plant and equipment	(8,783)		(9,398)
Payments related to business acquisition, net of cash acquired		—		(142,555)
Other		(1,000)		—
Purchases of property, plant and equipment
Purchases of property, plant and equipment

Net cash used in investing activities

Net cash used in investing activities

Net cash used in investing activities	Net cash used in investing activities	(9,783)		(151,953)

Cash flows from financing activities:	Cash flows from financing activities:
Payments on term loan		—		(92,981)
Cash flows from financing activities:
Cash flows from financing activities:

Payments on revolving line of credit

Payments on revolving line of credit

Payments on revolving line of credit	Payments on revolving line of credit	(347,000)		(312,000)
Proceeds from revolving line of credit	Proceeds from revolving line of credit	331,000		172,000
Payments to redeem convertible notes	Payments to redeem convertible notes	—		(275,000)
Proceeds from issuance of convertible notes		—		800,000

Payments related to debt issuance costs		—		(21,187)
Payments related to contingent consideration
Payments related to contingent consideration
Payments related to contingent consideration

Dividends paid on common stock	Dividends paid on common stock	(12,208)		(11,773)
Purchases of convertible notes hedge transactions		—		(187,600)
Proceeds from issuance of warrants		—		72,000
Proceeds from settlement of convertible notes hedge transactions		—		86,228
Payment for settlement of warrants		—		(69,534)
Dividends paid on common stock
Dividends paid on common stock

Other, net

Other, net

Other, net	Other, net	13,771		6,457
Net cash provided by (used in) financing activities	Net cash provided by (used in) financing activities	(14,437)		166,610

Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	300		(1,422)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents

Net increase (decrease) in cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Net increase (decrease) in cash and cash equivalents	Net increase (decrease) in cash and cash equivalents	(1,094)		32,305

Cash and cash equivalents at beginning of period	Cash and cash equivalents at beginning of period	28,942		20,847
Cash and cash equivalents at beginning of period
Cash and cash equivalents at beginning of period

Cash and cash equivalents at end of period
Cash and cash equivalents at end of period
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	$	27,848	$	53,152

Non-cash investing and financing activities:	Non-cash investing and financing activities:
Non-cash investing and financing activities:
Non-cash investing and financing activities:

Contingent consideration		$	—	$	69,402

Dividends payable	Dividends payable	$	6,145	$	6,092

Dividends payable

Dividends payable

See notes to consolidated condensed financial statements.

Table of Contents

CONMED CORPORATION

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(Unaudited, in thousands except per share amounts)

Note 1 - Operations

CONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology.

Note 2 - Interim Financial Information

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements. The information herein reflects all normal recurring material adjustments, which are, in the opinion of management, necessary to fairly present the results for the periods presented. The consolidated condensed financial statements herein consist of all wholly-owned domestic and foreign subsidiaries with all significant intercompany transactions eliminated. Results for the period ended ~~June 30, 2023~~March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2023.~~2024.

The consolidated condensed financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended December 31, ~~2022~~2023 included in our Annual Report on Form 10-K.

Use of Estimates

~~Preparation~~The preparation of the consolidated condensed financial statements in conformity with ~~U.S. GAAP~~accounting principles generally accepted in the United States of America requires management to make estimates and ~~assumptions that~~judgments which affect the reported amounts of assets, ~~and~~ liabilities and ~~disclosure~~related disclosures of contingent assets and liabilities at the date of the consolidated condensed financial statements and the reported ~~amounts~~amount of revenue and expenses during the reporting period.

While there has been uncertainty and disruption in the global economy and financial markets, we are not aware of any specific event or circumstance that would require an update to our estimates or judgments or a revision of the carrying value of our assets or liabilities as of ~~July 27, 2023,~~April 25, 2024, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

Note 3 - New Accounting Pronouncements

Recently Issued Accounting Standards, Not Yet Adopted

In ~~March 2020,~~December 2023, the Financial Accounting Standards Board ("FASB") issued ASU ~~2020-04, Reference Rate Reform~~2023-09 - Income Taxes (Topic ~~848)~~740): ~~Facilitation of the Effects of Reference Rate Reform~~Improvements to Income Tax Disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation in specified categories as well as information on Financial Reporting, which provides optional guidance if certain criteria are met for entities that have contracts, hedging relationships, and other transactions that reference LIBOR or other reference rates expected to be discontinued as a result of reference rate reform.income taxes paid. This ASU is effective ~~as of March 12, 2020 through~~for annual periods beginning after December ~~31, 2022~~15, 2024 and ~~was extended through December 31, 2024 by~~early adoption is permitted. This ASU ~~2022-06, Reference Rate Reform (Topic 848): Deferral of~~should be applied on a prospective basis with retrospective application permitted. We expect this ASU to only impact our disclosures with no impact to the Sunset Date of Topic 848. The Company has not adopted these ASUs as of June 30, 2023. Our seventh amended and restated senior credit agreement includes language to address the change from LIBOR to SOFR, an alternative base rate, therefore we do not believe reference rate reform will have a significant impact on our consolidated financial statements.

~~Note 4~~In November 2023, the FASB issued ASU 2023-07 - ~~Business Combinations~~Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose significant segment expenses and other segment items on an annual and interim basis, and provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. The ASU does not change how a public entity identifies its operating segments, aggregates them or applies the quantitative threshold to determine its reportable segments. The new disclosure requirements are also applicable to entities that account and report as a single operating segment entity. This ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied retrospectively to all prior periods presented. We expect this ASU to only impact our disclosures with no impact to the consolidated financial statements.

On June 13, 2022, we acquired In2Bones Global, Inc. ("In2Bones") and all of its stock (the "In2Bones Acquisition") for an aggregate upfront payment of $145.2 million in cash. In addition, there are potential earn-out payments to In2Bones’ equity holders in an amount up to $110.0 million based on the achievement of certain revenue targets for In2Bones products during the sixteen (16) successive quarters commencing on July 1, 2022. In2Bones is a global developer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the lower extremities (foot and ankle). The

Table of Contents

In2Bones Acquisition was funded through a combination of cash on hand and long-term borrowings as further described in Note 11. Proforma information for In2Bones is immaterial for disclosure for the three and six months ended June 30, 2023 and 2022.

Recently Adopted SEC Rules

In March 2024, the SEC adopted the final rule under SEC Release Nos. 33-11275 and 34-99678, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which will require registrants to provide certain climate-related information in their registration statements and annual reports. The disclosure requirements follow a phase-in timeline, with initial requirements beginning with the filing of the 2025 Form 10-K. We ~~incurred costs~~are currently evaluating the final rule to determine the impact on our disclosures. On April 4, 2024, the SEC issued an order staying the final rule pending the completion of judicial review of the petitions challenging the final rule filed in six different circuit courts, which have been consolidated for review by the U.S. Court of Appeals for the amortization of inventory step-up to fair value of $2.2 million and $4.3 million during the three and six months ended June 30, 2023, respectively, and $0.3 million during both the three and six months ended June 30, 2022 related to the In2Bones acquisition, which were recorded in cost of sales. During the three and six months ended June 30, 2023, we recognized $0.2 million and $0.5 million, respectively, in integration costs and professional fees related to the acquisition that were included in selling and administrative expense. During the three and six months ended June 30, 2022, we recognized $2.6 million in consulting and legal related fees associated with the acquisition of In2Bones, which were included in selling and administrative expense.Eighth Circuit.

On August 9, 2022, we acquired Biorez, Inc. ("Biorez") and all of its stock (the "Biorez Acquisition") for an aggregate upfront payment of $85.5 million in cash. We paid $83.9 million as of June 30, 2023, with a $1.6 million holdback, pursuant to the merger agreement for the Biorez Acquisition. In addition, there are potential earn-out payments to Biorez’ equity holders in an amount up to $165.0 million based on the achievement of certain revenue targets for Biorez products during the sixteen (16) successive quarters commencing on October 1, 2022. Biorez is a medical device start-up focused on advancing the healing of soft tissue using its proprietary BioBrace® implant technology. The Biorez Acquisition was funded through a combination of cash on hand and long-term borrowings. Proforma information is immaterial for disclosure for the three and six months ended June 30, 2023 and 2022.

~~Table of Contents~~

Note 54 - Revenues

The following tables present revenue disaggregated by primary geographic market where the products are sold, by product line and timing of revenue recognition:


		Three Months Ended						Three Months Ended
		June 30, 2023						June 30, 2022
	Three Months Ended																	Three Months Ended
	March 31, 2024															March 31, 2024					March 31, 2023
		Orthopedic Surgery		General Surgery		Total		Orthopedic Surgery		General Surgery		Total		Orthopedic Surgery	General Surgery		Total		Orthopedic Surgery	General Surgery		Total
Primary Geographic Markets	Primary Geographic Markets
United States
United States
United States	United States	$	52,339	$	122,328	$	174,667	$	40,461	$	108,721	$	149,182
Europe, Middle East & Africa	Europe, Middle East & Africa	32,582		25,700		58,282		32,060		22,468		54,528
Asia Pacific	Asia Pacific	33,249		19,357		52,606		27,674		16,201		43,875
Americas (excluding the United States)	Americas (excluding the United States)	22,620		9,477		32,097		19,987		9,618		29,605
Total sales from contracts with customers	Total sales from contracts with customers	$	140,790	$	176,862	$	317,652	$	120,182	$	157,008	$	277,190

Timing of Revenue Recognition	Timing of Revenue Recognition
Timing of Revenue Recognition
Timing of Revenue Recognition
Goods transferred at a point in time
Goods transferred at a point in time
Goods transferred at a point in time	Goods transferred at a point in time	$	130,274	$	175,025	$	305,299	$	110,060	$	155,451	$	265,511
Services transferred over time	Services transferred over time	10,516		1,837		12,353		10,122		1,557		11,679
Total sales from contracts with customers	Total sales from contracts with customers	$	140,790	$	176,862	$	317,652	$	120,182	$	157,008	$	277,190

Six Months Ended Six Months Ended
June 30, 2023 June 30, 2022
Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total
Primary Geographic Markets
United States $ 101,284 $ 237,973 $ 339,257 $ 78,408 $ 202,001 $ 280,409
Europe, Middle East & Africa 65,702 48,596 114,298 62,041 42,794 104,835
Asia Pacific 63,370 35,343 98,713 51,091 29,155 80,246
Americas (excluding the United States) 41,610 19,243 60,853 36,158 17,868 54,026
Total sales from contracts with customers $ 271,966 $ 341,155 $ 613,121 $ 227,698 $ 291,818 $ 519,516
Timing of Revenue Recognition
Goods transferred at a point in time $ 251,397 $ 337,614 $ 589,011 $ 208,264 $ 288,773 $ 497,037
Services transferred over time 20,569 3,541 24,110 19,434 3,045 22,479
Total sales from contracts with customers $ 271,966 $ 341,155 $ 613,121 $ 227,698 $ 291,818 $ 519,516

Contract liability balances related to the sale of extended warranties to customers are as follows:

June 30, 2023 December 31, 2022
Contract liability $ 18,604 $ 19,114


	March 31, 2024		December 31, 2023

Contract liability	$	18,319	$	17,962

Revenue recognized during the ~~six~~three months ended ~~June 30,~~March 31, 2024 and March 31, 2023 ~~and June 30, 2022~~ from amounts included in contract liabilities at the beginning of the period were ~~$7.6~~$4.8 million and ~~$7.0~~$4.2 million, respectively. There were no material contract assets as of ~~June 30, 2023~~March 31, 2024 and December 31, ~~2022.~~2023.

Table of Contents

Note 65 - Comprehensive Income ~~(Loss)~~

Comprehensive income ~~(loss)~~ consists of the following:

Three Months Ended June 30, Six Months Ended June 30,
2023 2022 2023 2022
Net income (loss) $ 13,732 $ (168,291) $ 15,551 $ (153,316)
Other comprehensive income (loss):
Cash flow hedging gain, net of income tax (income tax expense of $161 and $1,491 for the three months ended June 30, 2023 and 2022, respectively, and $442 and $1,838 for the six months ended June 30, 2023 and 2022, respectively) 503 4,662 1,381 5,744
Pension liability, net of income tax (income tax expense of $129 and $158 for the three months ended June 30, 2023 and 2022, respectively, and $258 and $284 for the six months ended June 30, 2023 and 2022, respectively.) 403 490 806 1,012
Foreign currency translation adjustment 1,129 (9,497) 2,724 (9,661)
Comprehensive income (loss) $ 15,767 $ (172,636) $ 20,462 $ (156,221)


	Three Months Ended March 31,
	2024		2023
Net income	$	19,709	$	1,819

Other comprehensive income:
Cash flow hedging gain, net of income tax (income tax expense of $1,423 and $280 for the three months ended March 31, 2024 and 2023, respectively)	4,448		877
Pension liability, net of income tax (income tax expense of $96 and $129 for the three months ended March 31, 2024 and 2023, respectively)	301		403
Foreign currency translation adjustment	(4,380)		1,596

Comprehensive income	$	20,078	$	4,695

Accumulated other comprehensive loss consists of the following:

Cash Flow
Hedging
Gain (Loss) Pension
Liability Cumulative
Translation
Adjustments Accumulated
Other
Comprehensive
Income (Loss)
Balance, December 31, 2022 $ 2,497 $ (23,749) $ (36,606) $ (57,858)
Other comprehensive income before reclassifications, net of tax 4,010 — 2,724 6,734
Amounts reclassified from accumulated other comprehensive income (loss) before taxa
(3,471) 1,064 — (2,407)
Income tax 842 (258) — 584
Net current-period other comprehensive income 1,381 806 2,724 4,911
Balance, June 30, 2023 $ 3,878 $ (22,943) $ (33,882) $ (52,947)


	Cash Flow Hedging Gain (Loss)		Pension Liability		Cumulative Translation Adjustments		Accumulated Other Comprehensive Loss
Balance, December 31, 2023	$	117	$	(18,766)	$	(31,521)	$	(50,170)

Other comprehensive income (loss) before reclassifications, net of tax	5,499		—		(4,380)		1,119
Amounts reclassified from accumulated other comprehensive income (loss) before taxa	(1,387)		398		—		(989)
Income tax	336		(97)		—		239

Net current-period other comprehensive income (loss)	4,448		301		(4,380)		369

Balance, March 31, 2024	$	4,565	$	(18,465)	$	(35,901)	$	(49,801)

Cash Flow
Hedging
Gain (Loss) Pension
Liability Cumulative
Translation
Adjustments Accumulated
Other
Comprehensive
Income (Loss)
Balance, December 31, 2021 $ 3,656 $ (29,671) $ (28,188) $ (54,203)
Other comprehensive income (loss) before reclassifications, net of tax 9,851 — (9,661) 190
Amounts reclassified from accumulated other comprehensive income (loss) before taxa
(5,421) 1,296 — (4,125)
Income tax 1,314 (284) — 1,030
Net current-period other comprehensive income (loss) 5,744 1,012 (9,661) (2,905)
Balance, June 30, 2022 $ 9,400 $ (28,659) $ (37,849) $ (57,108)


	Cash Flow Hedging Gain (Loss)		Pension Liability		Cumulative Translation Adjustments		Accumulated Other Comprehensive Loss
Balance, December 31, 2022	$	2,497	$	(23,749)	$	(36,606)	$	(57,858)

Other comprehensive income before reclassifications, net of tax	1,923		—		1,596		3,519
Amounts reclassified from accumulated other comprehensive income (loss) before taxa	(1,381)		532		—		(849)
Income tax	335		(129)		—		206

Net current-period other comprehensive income	877		403		1,596		2,876

Balance, March 31, 2023	$	3,374	$	(23,346)	$	(35,010)	$	(54,982)

(a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive loss components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 76 and Note ~~13,~~12, respectively, for further details.

Table of Contents

Note 76 - Fair Value of Financial Instruments

We enter into derivative instruments for risk management purposes only. We operate internationally and, in the normal course of business, are exposed to fluctuations in interest rates, foreign exchange rates and commodity prices. These fluctuations can increase the costs of financing, investing and operating the business. We use forward contracts, a type of derivative instrument, to manage certain foreign currency exposures.

By nature, all financial instruments involve market and credit risks. We enter into forward contracts with major investment grade financial institutions and have policies to monitor the credit risk of those counterparties. While there can be no assurance, we do not anticipate any material non-performance by any of these counterparties.

Foreign Currency Forward Contracts. We hedge forecasted intercompany sales denominated in foreign currencies through the use of forward contracts. We account for these forward contracts as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings ~~(loss)~~ but are included in accumulated other comprehensive loss. These changes in fair value will be recognized into earnings ~~(loss)~~ as a component of sales or cost of sales when the forecasted transaction occurs.

We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency transaction exposures on intercompany receivables designated in foreign currencies. These forward contracts settle each month at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and have not applied hedge accounting to them.

The following table presents the notional contract amounts for forward contracts outstanding:

As of

FASB ASC Topic 815 Designation

June 30, 2023

December 31, 2022

As of

FASB ASC Topic 815 Designation

March 31, 2024

December 31, 2023

Forward exchange contracts

Cash flow hedge

214,933

198,473

Forward exchange contracts

Non-designated

80,528

81,929

The remaining time to maturity as of ~~June 30, 2023~~March 31, 2024 is within two years for hedge designated foreign exchange contracts and approximately one month for non-hedge designated forward exchange contracts.

108

Table of Contents

Statement of comprehensive income ~~(loss)~~ presentation

Derivatives designated as cash flow hedges

Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) ("AOCI") and net earnings on our consolidated condensed statements of comprehensive income ~~(loss)~~ and our consolidated condensed balance sheets:


			Amount of Gain Recognized in AOCI				Consolidated Condensed Statements of Comprehensive Income (Loss)						Amount of Gain Reclassified from AOCI
			Three Months Ended June 30,
									Total Amount of Line Item Presented
		Amount of Gain Recognized in AOCI																	Amount of Gain Recognized in AOCI			Consolidated Condensed Statements of Comprehensive Income			Amount of Gain Reclassified from AOCI
		Three Months Ended March 31,																						Three Months Ended March 31,
								Total Amount of Line Item Presented
Derivative Instrument
Derivative Instrument
Derivative Instrument	Derivative Instrument		2023		2022		Location of amount reclassified		2023		2022		2023		2022		2024	2023		Location of amount reclassified	2024	2023	2024		2023

Foreign exchange contracts
Foreign exchange contracts
Foreign exchange contracts	Foreign exchange contracts		$	2,753	$	9,756	Net Sales		$	317,652	$	277,190	$	915	$	3,403
							Cost of Sales		146,962		125,413		1,175		199
Pre-tax gain	Pre-tax gain		$	2,753	$	9,756							$	2,090	$	3,602
Tax expense	Tax expense		667		2,365								507		873
Net gain	Net gain		$	2,086	$	7,391							$	1,583	$	2,729

Amount of Gain Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain Reclassified from AOCI
Six Months Ended June 30,
Total Amount of Line Item Presented
Derivative Instrument 2023 2022 Location of amount reclassified 2023 2022 2023 2022
Foreign exchange contracts $ 5,291 $ 13,003 Net Sales $ 613,121 $ 519,516 $ 1,490 $ 5,147
Cost of Sales 287,110 231,748 1,981 274
Pre-tax gain $ 5,291 $ 13,003 $ 3,471 $ 5,421
Tax expense 1,281 3,152 842 1,314
Net gain $ 4,010 $ 9,851 $ 2,629 $ 4,107

At ~~June 30, 2023, $3.5~~March 31, 2024, $4.1 million of net unrealized gains on forward contracts accounted for as cash flow hedges, and included in accumulated other comprehensive loss, are expected to be recognized in earnings in the next twelve months.

~~Table of Contents~~

Derivatives not designated as cash flow hedges

Net gains (losses) from derivative instruments not accounted for as hedges and ~~losses~~gains (losses) on our intercompany receivables on our consolidated condensed statements of comprehensive income ~~(loss)~~ were:

Three Months Ended June 30, Six Months Ended June 30,
Derivative Instrument Location on Consolidated Condensed Statements of Comprehensive Income (Loss) 2023 2022 2023 2022

Net gain on currency forward contracts Selling and administrative expense $ 768 $ 1,155 $ 403 $ 196
Net loss on currency transaction exposures Selling and administrative expense $ (1,355) $ (2,178) $ (1,279) $ (1,764)


		Three Months Ended March 31,
Derivative Instrument	Location on Consolidated Condensed Statements of Comprehensive Income	2024		2023

Net gain (loss) on currency forward contracts	Selling and administrative expense	$	671	$	(366)
Net gain (loss) on currency transaction exposures	Selling and administrative expense	$	(1,245)	$	76

Table of Contents

Balance sheet presentation

We record these forward foreign exchange contracts at fair value. The following tables summarize the fair value for forward foreign exchange contracts outstanding at ~~June 30, 2023~~March 31, 2024 and December 31, ~~2022:~~2023:


June 30, 2023		Location on Consolidated Condensed Balance Sheet		Asset Fair Value		Liabilities Fair Value		Net Fair Value
March 31, 2024										March 31, 2024	Location on Consolidated Condensed Balance Sheet	Asset Fair Value	Liabilities Fair Value	Net Fair Value
Derivatives designated as hedged instruments:	Derivatives designated as hedged instruments:									Derivatives designated as hedged instruments:
Foreign exchange contracts	Foreign exchange contracts	Prepaid expenses and other current assets		$	6,845	$	(2,283)	$	4,562
Foreign exchange contracts	Foreign exchange contracts	Other assets		1,240		(684)		556
			$
				$	8,085	$	(2,967)	$	5,118

Derivatives not designated as hedging instruments:
Derivatives not designated as hedging instruments:
Derivatives not designated as hedging instruments:	Derivatives not designated as hedging instruments:
Foreign exchange contracts	Foreign exchange contracts	Other current liabilities		15		(224)		(209)

Total derivatives	Total derivatives			$	8,100	$	(3,191)	$	4,909
Total derivatives
Total derivatives


December 31, 2022		Location on Consolidated Condensed Balance Sheet		Asset Fair Value		Liabilities Fair Value		Net Fair Value
December 31, 2023										December 31, 2023	Location on Consolidated Condensed Balance Sheet	Asset Fair Value	Liabilities Fair Value	Net Fair Value
Derivatives designated as hedged instruments:	Derivatives designated as hedged instruments:
Foreign exchange contracts	Foreign exchange contracts	Prepaid expenses and other current assets		$	6,757	$	(3,121)	$	3,636
Foreign exchange contracts	Foreign exchange contracts	Other long-term liabilities		60		(400)		(340)
				$	6,817	$	(3,521)	$	3,296
Foreign exchange contracts
Foreign exchange contracts
			$

Derivatives not designated as hedging instruments:	Derivatives not designated as hedging instruments:
Derivatives not designated as hedging instruments:
Derivatives not designated as hedging instruments:
Foreign exchange contracts
Foreign exchange contracts
Foreign exchange contracts	Foreign exchange contracts	Other current liabilities		48		(395)		(347)

Total derivatives	Total derivatives			$	6,865	$	(3,916)	$	2,949
Total derivatives
Total derivatives

~~Table of Contents~~

Our forward foreign exchange contracts are subject to a master netting agreement and qualify for netting in the consolidated condensed balance sheets.

Fair Value Disclosure. FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. This guidance applies when fair value measurements are required or permitted. The guidance indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is defined based upon an exit price model.

Valuation Hierarchy. A valuation hierarchy was established for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from or corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. There have been no significant changes in the assumptions.

Table of Contents

Valuation Techniques. Assets and liabilities carried at fair value and measured on a recurring basis as of ~~June 30, 2023~~March 31, 2024 consist of forward foreign exchange contracts and contingent consideration. The Company values its forward foreign exchange contracts using quoted prices for similar assets. The most significant assumption is quoted currency rates. The value of the forward foreign exchange contract assets and liabilities were valued using Level 2 inputs and are listed in the table above.

The Company values contingent consideration from the In2Bones and Biorez acquisitions using Level 3 inputs. The contingent consideration was recorded at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, revenue volatilities and projected revenues. The recurring Level 3 fair value measurements of contingent consideration for which the liabilities are recorded include the following significant unobservable inputs as of ~~June 30, 2023:~~March 31, 2024:

Assumptions

Unobservable Input

In2Bones

Biorez

Unobservable Input

In2Bones

Biorez

Discount rate

7.41%

12.02%

Discount rate

8.21%

13.11%

Revenue volatility

13.56%

20.62%

Revenue volatility

18.62%

22.08%

Projected year of payment

2023-2026

Projected year of payment

2024-2026

Adjustments to the fair value of contingent consideration relate to the passage of time and changes in market assumptions. Changes in the fair value of contingent consideration liabilities for the ~~six~~three months ended ~~June 30,~~March 31, 2024 and 2023 are as follows:

In2Bones Biorez Location in Financial Statements
Balance as of January 1, 2023 $ 70,198 $ 116,234
Changes in fair value of contingent consideration 136 3,663 Selling and administrative expense
Balance as of June 30, 2023 $ 70,334 $ 119,897


	In2Bones				Biorez
	2024		2023		2024		2023
Balance as of January 1,	$	41,393	$	70,198	$	128,751	$	116,234

Payments	(2,187)		—		(24,741)		—
Changes in fair value of contingent consideration	(8,561)		2,637		2,016		1,799

Balance as of March 31,	$	30,645	$	72,835	$	106,026	$	118,033

Contingent consideration of ~~$73.1~~$56.6 million and ~~$117.1~~$80.0 million is included in other current liabilities and other long-term liabilities, respectively, in the consolidated condensed balance sheet at ~~June 30, 2023.~~March 31, 2024. Contingent consideration of ~~$18.6~~$77.6 million and ~~$167.8~~$92.5 million is included in other current liabilities and other long-term liabilities, respectively, in the consolidated condensed balance sheet at December 31, ~~2022.~~2023.

The carrying amounts reported in our consolidated condensed balance sheets for cash and cash equivalents, accounts receivable, accounts payable and variable long-term debt approximate fair value.

Note 7 - Inventories

Inventories consist of the following:


	March 31, 2024		December 31, 2023
Raw materials	$	105,239	$	107,262
Work-in-process	28,793		29,463
Finished goods	188,266		181,599
Total	$	322,298	$	318,324

Table of Contents

Note 8 - ~~Inventories~~

~~Inventories consist of the following:~~

June 30,
2023 December 31,
2022
Raw materials $ 123,951 $ 110,677
Work-in-process 27,797 26,166
Finished goods 175,561 195,477
Total $ 327,309 $ 332,320

~~Note 9 -~~ Earnings ~~(Loss)~~ Per Share

Basic earnings ~~(loss)~~ per share (“basic EPS”) is computed by dividing net income ~~(loss)~~ by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share ~~for the three and six months ended June 30, 2023~~ (“diluted EPS”) gives effect to all dilutive potential shares. ~~As the Company was in a net loss position for the three and six months ended June 30, 2022, there were no dilutive potential shares included in the computation of diluted shares outstanding.~~

The following tables set forth the computation of basic and diluted earnings ~~(loss)~~ per share ~~as applicable,~~ for the three ~~and six~~ months ended ~~June 30, 2023~~March 31, 2024 and ~~2022:~~2023:

Three Months Ended June 30, 2023 Three Months Ended June 30, 2022
Basic EPS Adjustments Diluted EPS Basic EPS Adjustments Diluted EPS
Net income (loss) $ 13,732 $ — $ 13,732 $ (168,291) $ — $ (168,291)
Weighted average shares outstanding 30,662 — 30,662 29,775 — 29,775
Stock compensation — 874 874 — — —
Warrants — 45 45 — — —
Convertible notes — 214 214 — — —
30,662 1,133 31,795 29,775 — 29,775
EPS $ 0.45 $ 0.43 $ (5.65) $ (5.65)


	Three Months Ended March 31, 2024		Three Months Ended March 31, 2023

Net income	$	19,709	$	1,819

Basic weighted average shares outstanding	30,780		30,511

Stock compensation	492		629

Convertible notes	—		64

Diluted weighted average shares outstanding	31,272		31,204

Net income (per share)
Basic	$	0.64	$	0.06
Diluted	0.63		0.06

~~Table of Contents~~

Six Months Ended June 30, 2023 Six Months Ended June 30, 2022
Basic EPS Adjustments Diluted EPS Basic EPS Adjustments Diluted EPS
Net income (loss) $ 15,551 — $ 15,551 $ (153,316) — $ (153,316)
Weighted average shares outstanding 30,587 — 30,587 29,601 — 29,601
Stock compensation — 751 751 — — —
Warrants — 22 22 — — —
Convertible notes — 139 139 — — —
30,587 912 31,499 29,601 — 29,601
EPS $ 0.51 $ 0.49 $ (5.18) $ (5.18)

The shares used in the calculation of diluted EPS exclude stock options and stock appreciation rights to purchase shares where the exercise price was greater than the average market price of common shares for the period and the effect of the inclusion would be anti-dilutive. Such shares aggregated approximately ~~1.8~~2.5 million and ~~1.7~~2.2 million for the three ~~and six~~ months ended ~~June 30,~~March 31, 2024 and 2023, respectively. ~~As the Company was in a net loss position for the three and six months ended June 30, 2022, there were no anti-dilutive shares.~~

Note 109 - Goodwill and Other Intangible Assets

The changes in the net carrying amount of goodwill for the ~~six~~three months ended ~~June 30, 2023~~March 31, 2024 are as follows:


Balance as of December 31, ~~2022~~2023	$	~~815,429~~806,844



Foreign currency translation	~~205~~ (568)

Balance as of ~~June 30, 2023~~March 31, 2024	$	~~815,634~~806,276

Assets and liabilities of acquired businesses are recorded at their estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses.

1512

Table of Contents

Other intangible assets consist of the following:


		June 30, 2023					December 31, 2022				March 31, 2024				December 31, 2023
		Weighted Average Amortization Period (Years)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
	Weighted Average Amortization Period (Years)											Weighted Average Amortization Period (Years)	Gross Carrying Amount	Accumulated Amortization		Gross Carrying Amount	Accumulated Amortization
Intangible assets with definite lives:	Intangible assets with definite lives:	22

Customer and distributor relationships	Customer and distributor relationships	24	$	369,888	$	(179,698)	$	369,854	$	(170,870)

Customer and distributor relationships

Customer and distributor relationships

Sales representation, marketing and promotional rights
Sales representation, marketing and promotional rights
Sales representation, marketing and promotional rights	Sales representation, marketing and promotional rights	25	149,376		(69,000)		149,376		(66,000)

Developed technology	Developed technology	18	320,204		(39,616)		320,204		(34,675)
Developed technology
Developed technology

Patents and other intangible assets
Patents and other intangible assets
Patents and other intangible assets	Patents and other intangible assets	16	81,139		(53,253)		79,838		(52,472)

Intangible assets with indefinite lives:	Intangible assets with indefinite lives:
Intangible assets with indefinite lives:
Intangible assets with indefinite lives:

Trademarks and tradenames	Trademarks and tradenames		86,544		—		86,544		—
Trademarks and tradenames
Trademarks and tradenames

			$	1,007,151	$	(341,567)	$	1,005,816	$	(324,017)
			$
			$
			$

Customer and distributor relationships, trademarks and tradenames, developed technology and patents and other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. Sales representation, marketing and promotional rights represent intangible assets created under our agreement with Musculoskeletal Transplant Foundation (“MTF”).

Amortization expense related to intangible assets which are subject to amortization totaled ~~$8.8~~$8.6 million and ~~$8.2~~$8.8 million for the three months ended ~~June 30,~~March 31, 2024 and 2023, ~~and 2022, respectively, and $17.6 million and $16.2 million for the six months ended June 30, 2023 and 2022,~~ respectively, and is included as a reduction of revenue (for amortization related to our sales representation, marketing and promotional rights) and in selling and administrative expense (for all other intangible assets) in the consolidated condensed statements of comprehensive ~~income (loss).~~income.

The estimated intangible asset amortization expense remaining for the year ending December 31, ~~2023~~2024 and for each of the five succeeding years is as follows:


		Amortization included in expense		Amortization recorded as a reduction of revenue		Total
Remaining, 2023		$	14,671	$	3,000	$	17,671
2024		28,810		6,000		34,810
	Amortization included in expense							Amortization included in expense	Amortization recorded as a reduction of revenue	Total
Remaining, 2024
2025	2025	29,632		6,000		35,632
2026	2026	29,396		6,000		35,396
2027	2027	30,436		6,000		36,436
2028	2028	33,568		6,000		39,568
2029

1613

Table of Contents

Note 1110 - Long-Term Debt

Long-term debt consists of the following:


		June 30, 2023		December 31, 2022		March 31, 2024	December 31, 2023
Revolving line of credit	Revolving line of credit	$	54,000	$	70,000
Term loan, net of deferred debt issuance costs of $627 and $729 in 2023 and 2022, respectively		133,961		133,858
2.625% convertible notes, net of deferred debt issuance costs of $232 and $432 in 2023 and 2022, respectively		69,768		69,568
2.250% convertible notes, net of deferred debt issuance costs of $16,708 and $18,834 in 2023 and 2022, respectively		783,292		781,166
Term loan, net of deferred debt issuance costs of $472 and $524 in 2024 and 2023, respectively
2.625% convertible notes
2.250% convertible notes, net of deferred debt issuance costs of $13,517 and $14,581 in 2024 and 2023, respectively
Financing leases	Financing leases	86		230
Total debt	Total debt	1,041,107		1,054,822
Less: Current portion	Less: Current portion	69,632		69,746
Total long-term debt	Total long-term debt	$	971,475	$	985,076

Seventh Amended and Restated Senior Credit Agreement

On July 16, 2021, we entered into a seventh amended and restated senior credit agreement consisting of: (a) a $233.5 million term loan facility and (b) a $585.0 million revolving credit facility. The revolving credit facility will terminate and the loans outstanding under the term loan facility will expire on July 16, 2026. The term loan was payable in quarterly installments increasing over the term of the facility. During 2022, we made a $90.0 million prepayment on the term loan facility resulting in the elimination of such quarterly payments with the remaining balance due upon the expiration of the term loan facility. The $90.0 million prepayment was accounted for as an extinguishment and resulted in a write-off to other expense of unamortized debt issuance costs of $0.5 million for the three and six months ended June 30, 2022. Proceeds from the term loan facility and borrowings under the revolving credit facility were used to repay the then existing senior credit agreement. Interest rates are at the ~~term~~Term Secured Overnight Financing Rate plus 0.114% ("Adjusted Term SOFR") ~~(5.239%~~(5.489% at ~~June 30, 2023)~~March 31, 2024) plus an interest rate margin of 1.125% ~~(6.364%~~(6.614% at ~~June 30, 2023)~~March 31, 2024). For borrowings where we elect to use the alternate base rate, the initial base rate is the greatest of (i) the Prime Rate, (ii) the Federal Funds Rate plus 0.50% or (iii) the one-month Adjusted Term SOFR plus 1.00%, plus, in each case, an interest rate margin.

There were ~~$134.6~~$114.6 million in borrowings outstanding on the term loan facility as of ~~June 30, 2023.~~March 31, 2024. There were ~~$54.0~~$88.0 million in borrowings outstanding under the revolving credit facility as of ~~June 30, 2023.~~March 31, 2024. Our available borrowings on the revolving credit facility at ~~June 30, 2023~~March 31, 2024 were ~~$529.4~~$495.4 million with approximately $1.6 million of the facility set aside for outstanding letters of credit. The carrying amounts of the term loan and revolving credit facility approximate fair value.

The seventh amended and restated senior credit agreement is collateralized by substantially all of our personal property and assets. The seventh amended and restated senior credit agreement contains covenants and restrictions which, among other things, require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of ~~June 30, 2023.~~March 31, 2024. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds from any issuance of equity and asset sales.

2.625% Convertible Notes

On January 29, 2019, we issued $345.0 million aggregate principal amount of 2.625% convertible notes that were due in 2024 (the "2.625% Notes"). Interest iswas payable semi-annually in arrears on February 1 and August 1 of each year, commencing August 1, 2019. The 2.625% Notes ~~will~~were scheduled to mature on February 1, 2024, unless earlier repurchased or converted.

The 2.625% Notes ~~represent~~represented subordinated unsecured obligations and ~~are~~were convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The 2.625% Notes ~~may be~~could have been converted at an initial conversion rate of 11.2608 shares of our common stock per $1,000 principal amount of 2.625% Notes (equivalent to an initial conversion price of approximately $88.80 per share of common stock). Holders of the 2.625% Notes ~~may convert~~could have converted the 2.625% Notes at their option at any time on or after November 1, 2023 through the second scheduled trading day preceding the maturity date. Holders of the 2.625% Notes ~~will~~ also ~~have~~had the right to convert the 2.625% Notes prior to November 1, 2023, but only upon the occurrence of specified events. The conversion rate iswas subject to anti-dilution adjustments if certain events ~~occur.~~occurred. A portion of the net proceeds from the offering of the 2.625% Notes was used as part of

1714

Table of Contents

~~proceeds from the offering of the 2.625% Notes were used as part of~~ the financing for the Buffalo Filter acquisition and $21.0 million were used to pay the cost of certain convertible notes hedge transactions as further described below.

On June 6, 2022, the Company repurchased and extinguished $275.0 million principal amount of the 2.625% Notes for aggregate consideration consisting of $275.0 million in cash and approximately 0.9 million shares of the Company's common stock. During the three and six months ended June 30, 2022, the Company recorded a loss on extinguishment of $103.1 million to other expense based on the fair value of the shares of the Company’s common stock issued in connection with the extinguishment. This loss was not deductible for tax purposes.~~We also recorded a write-off to other expense of unamortized debt issuance costs related to the 2.625% Notes of $2.9 million.~~ Concurrently, the Company entered into a Supplemental Indenture related to the remaining $70.0 million in 2.625% Notes, in which the Company irrevocably elected to settle the principal value of those 2.625% Notes in cash. ~~The~~In February 2024, the Company repaid the remaining $70.0 million inthen outstanding of the 2.625% Notes ~~are reflected in~~through borrowings on our revolving credit facility and issued 0.1 million shares of the ~~current portion of long-term debt at June 30, 2023.~~Company's common stock.

For the three months ended ~~June 30,~~March 31, 2024 and 2023, ~~and 2022,~~ we have recorded interest expense on the 2.625% Notes of ~~$0.5~~$0.2 million and ~~$1.7 million, respectively, and for the six months ended June 30, 2023 and 2022, we have recorded interest expense on the 2.625% Notes of $0.9 million and $3.9~~$0.5 million, respectively, at the contractual coupon rate of 2.625%.

The estimated fair value of the 2.625% Notes was approximately $105.9 million as of June 30, 2023 based on a market approach which represents a Level 2 valuation in the fair value hierarchy. The estimated fair value was determined based on the estimated or actual bids and offers of the 2.625% Notes in an over-the-counter market transaction on the last business day of the period.

2.250% Convertible Notes

On June 6, 2022, we issued $800.0 million aggregate principal amount of 2.250% Notes.Interest is payable semi-annually in arrears on June 15 and December 15 of each year, commencing December 15, 2022.The 2.250% Notes will mature on June 15, 2027, unless earlier repurchased or converted. The 2.250% Notes represent subordinated unsecured obligations and are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock, with the principal required to be paid in cash. The 2.250% Notes may be converted at an initial conversion rate of 6.8810 shares of our common stock per $1,000 principal amount of the 2.250% Notes (equivalent to an initial conversion price of approximately $145.33 per share of common stock). Holders of the 2.250% Notes may convert the 2.250% Notes at their option at any time on or after March 15, 2027 through the second scheduled trading day preceding the maturity date. Holders of the 2.250% Notes will also have the right to convert the 2.250% Notes prior to March 15, 2027, but only upon the occurrence of specified events. The conversion rate is subject to anti-dilution adjustments if certain events occur. A portion of these proceeds were used to repurchase and extinguish a portion of the 2.625% Notes, pay off our then outstanding balance on our revolving line of credit, pay down of $90.0 million of our term loan and partially pay for the In2Bones Acquisition. In addition, approximately $115.6 million of the proceeds were used to pay the cost of certain convertible notes hedge transactions related to the 2.250% Notes.

For both the three months ended ~~June 30,~~March 31, 2024 and 2023, ~~and 2022,~~ we have recorded interest expense on the 2.250% Notes of $4.5 million ~~and $1.3 million, respectively, and for the six months ended June 30, 2023 and 2022, we have recorded interest expense on the 2.250% Notes of $9.0 million and $1.3 million, respectively,~~ at the contractual coupon rate of 2.250%.

The estimated fair value of the 2.250% Notes was approximately ~~$900.9~~$732.8 million as of ~~June 30, 2023~~March 31, 2024 based on a market approach which represents a Level 2 valuation in the fair value hierarchy. The estimated fair value was determined based on the estimated or actual bids and offers of the 2.250% Notes in an over-the-counter market transaction on the last business day of the period.

Convertible Notes Hedge Transactions

In connection with the offerings of the 2.625% and 2.250% Notes, we entered into convertible notes hedge transactions with a number of financial institutions (each, an “option counterparty”). The convertible notes hedge transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the respective Notes, the number of shares of our common stock underlying the 2.625% and 2.250% Notes. Concurrent with entering into the convertible notes hedge transactions, we also entered into separate warrant transactions with each option counterparty whereby we sold to such option counterparty warrants to purchase, subject to customary anti-dilution adjustments, the same number of shares of our common stock.

~~Table of Contents~~

In connection with the repurchase and extinguishment of $275.0 million principal amount of the 2.625% Notes, the Company entered into agreements with the option counterparties to terminate a corresponding portion of the hedges on the 2.625% Notes. ~~The Company recorded a $5.5 million charge to other expense as a result~~Upon maturity in February 2024 of ~~a subsequent decline in fair value between execution date~~the remaining 2.625% Notes and settlement ~~date during~~of the ~~three and six months ended June 30, 2022.~~related hedges, the Company received 0.1 million shares from the option counterparties.

The convertible notes hedge transactions are expected generally to reduce the potential dilution upon conversion of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, in the event that the market price per share of our common stock, as measured under the terms of the convertible notes hedge transactions, is greater than the strike price of the convertible notes hedge transactions, which initially corresponds

Table of Contents

to the conversion price of the Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the Notes. If, however, the market price per share of our common stock, as measured under the terms of the warrant transactions, exceeds the strike price ($~~114.92 for the 2.625% Notes and $251.53~~251.53 for the 2.250% Notes) of the warrants, there would nevertheless be dilution to the extent that such market price exceeds the strike price of the warrants, unless we elect to settle the warrants in cash.

The scheduled maturities of long-term debt outstanding at ~~June 30, 2023~~March 31, 2024 are as follows:


Remaining, 2023		$	70,000
2024		—
Remaining, 2024
2025	2025	—
2026	2026	188,588
2027	2027	800,000
2028	2028	—
2029

The above amounts exclude deferred debt issuance costs and financing leases.

Note 1211 - Guarantees

We provide warranties on certain of our products at the time of sale and sell extended warranties. The standard warranty period for our capital equipment is generally one year and our extended warranties typically vary from one to three years. Liability under service and warranty policies is based upon a review of historical warranty and service claim experience. Adjustments are made to accruals as claim data and historical experience warrant.

Changes in the liability for standard warranties for the ~~six~~three months ended ~~June 30,~~March 31, are as follows:


		2023		2022		2024	2023
Balance as of January 1,	Balance as of January 1,	$	1,944	$	2,344

Provision for warranties	Provision for warranties	304		113
Provision for warranties
Provision for warranties
Claims made	Claims made	(377)		(369)

Balance as of June 30,		$	1,871	$	2,088
Balance as of March 31,
Balance as of March 31,
Balance as of March 31,

Costs associated with extended warranty repairs are recorded as incurred and amounted to ~~$2.6~~$1.3 million and ~~$3.2~~$1.5 million for the ~~six~~three months ended ~~June 30,~~March 31, 2024 and 2023, ~~and 2022,~~ respectively.

1916

Table of Contents

Note 1312 - Pension Plan

Net periodic pension cost consists of the following:


		Three Months Ended March 31,
		Three Months Ended March 31,
		Three Months Ended March 31,

		Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022		2023		2022
Service cost	Service cost	$	194	$	269	$	388	$	538
Service cost
Service cost

Interest cost on projected benefit obligation

Interest cost on projected benefit obligation

Interest cost on projected benefit obligation	Interest cost on projected benefit obligation	911		537		1,822		1,074

Expected return on plan assets	Expected return on plan assets	(1,032)		(1,324)		(2,064)		(2,648)

Expected return on plan assets

Expected return on plan assets

Net amortization and deferral

Net amortization and deferral

Net amortization and deferral	Net amortization and deferral	532		648		1,064		1,296

Net periodic pension cost	Net periodic pension cost	$	605	$	130	$	1,210	$	260

Net periodic pension cost

Net periodic pension cost

We do not expect to make any pension contributions during ~~2023.~~2024. Non-service pension ~~cost/(benefit)~~cost was immaterial for the three ~~and six~~ months ended ~~June 30, 2023~~March 31, 2024 and ~~2022.~~2023.

Note 1413 - Business Segment

We are accounting and reporting for our business as a single operating segment entity engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Our chief operating decision maker (the CEO) evaluates the various global product portfolios on a net sales basis and evaluates profitability, investment, cash flow metrics and allocates resources on a consolidated worldwide basis due to shared infrastructure and resources. Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine and lower extremities instrumentation and implants, small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures and fees related to the sales representation, promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. These product lines' net sales are as follows:


		Three Months Ended March 31,
		Three Months Ended March 31,
		Three Months Ended March 31,

		Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022		2023		2022
Orthopedic surgery	Orthopedic surgery	$	140,790	$	120,182	$	271,966	$	227,698
Orthopedic surgery
Orthopedic surgery
General surgery
General surgery
General surgery	General surgery	176,862		157,008		341,155		291,818
Consolidated net sales	Consolidated net sales	$	317,652	$	277,190	$	613,121	$	519,516
Consolidated net sales
Consolidated net sales

Note 1514 - Legal Proceedings

From time to time, the Company may receive an information request, subpoena or warrant from a government agency such as the Securities and Exchange Commission, Department of Justice, Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, the United States Food and Drug Administration, the Department of Labor, the Treasury Department or other federal and state agencies or foreign governments or government agencies. These information requests, subpoenas or warrants may or may not be routine inquiries, or may begin as routine inquiries and over time develop into enforcement actions of various types. Likewise, if we receive reports of alleged misconduct from employees ~~and~~or third parties, we investigate as appropriate.

Manufacturers of medical devices have been the subject of various investigations and enforcement actions relating to interactions with health care providers domestically or internationally whereby companies are claimed to have provided health care providers with inappropriate incentives to purchase their products. Similarly, the Foreign Corrupt Practices Act ("FCPA") ~~imposes~~

2017

Table of Contents

prohibits U.S. companies and their representatives from offering or making payments to foreign officials for the purpose of securing a business advantage; and in many countries, the healthcare professionals with whom we regularly interact may meet the definition of a foreign government official for purposes of this law. Similar anti-bribery laws are in effect in many of the countries in which we operate. The FCPA also imposes obligations on manufacturers ~~with respect to interactions with health care providers who may be considered government officials based~~listed on ~~their affiliation with public hospitals. The FCPA also requires publicly listed manufacturers~~U.S. stock exchanges to maintain accurate books and records, and maintain internal accounting controls sufficient to provide assurance that transactions are accurately recorded, lawful and in accordance with ~~management's~~management’s authorization. The FCPA ~~poses~~can pose unique challenges ~~both because~~for manufacturers that operate in foreign cultures ~~in which~~where conduct ~~illegal under~~prohibited by the FCPA may not be viewed as illegal in local jurisdictions, and because, in some cases, a United States manufacturer may face risks under the FCPA based on the conduct of third parties (e.g., distributors) over whom the manufacturer may not have complete control. While CONMED has not experienced any material enforcement action to date, there can be no assurance that the Company will not be subject to a material enforcement action in the future, or that the Company will not incur costs including, in the form of fees for lawyers and other consultants, that are material to the Company’s results of operations in the course of responding to a future inquiry or investigation.

In addition, as a manufacturer of U.S. FDA-approved devices reimbursable by federal healthcare programs, we are subject to the Physician Payments Sunshine Act, which requires us to annually report certain payments and other transfers of value we make to U.S.-licensed physicians or U.S. teaching hospitals. Any failure to comply with these laws and regulations could subject us or our officers and employees to criminal and civil financial penalties.

Manufacturers of medical products may face exposure to significant product liability claims, as well as patent infringement and other claims incurred in the ordinary course of business. To date, we have not experienced any claims that have been material to our financial statements or financial condition, but any such claims arising in the future could have a material adverse effect on our business, results of operations or cash flows. We currently maintain commercial product liability insurance of $35 million per incident and $35 million in the aggregate annually, which we believe is adequate. This coverage is on a claims-made basis. There can be no assurance that claims will not exceed insurance coverage, that the carriers will be solvent or that such insurance will be available to us in the future at a reasonable cost.

Our operations are subject, and in the past have been subject, to a number of environmental laws and regulations governing, among other things, air emissions; wastewater discharges; the use, handling and disposal of hazardous substances and wastes; soil and groundwater remediation and employee health and safety. Likewise, the operations of our suppliers and sterilizers are subject to similar environmental laws and regulations. In some jurisdictions, environmental requirements may be expected to become more stringent in the future. In the United States, certain environmental laws can impose liability for the entire cost of site restoration upon each of the parties that may have contributed to conditions at the site regardless of fault or the lawfulness of the party’s activities. While we do not believe that the present costs of environmental compliance and remediation are material, there can be no assurance that future compliance or remedial obligations would not have a material adverse effect on our financial condition, results of operations or cash flows.

CONMED ishas been defending two Georgia State Court actions. The first action was filed in Cobb County by various employees, former employees, contract workers and others against CONMED and against a contract sterilizer (the "Cobb County Action"). ~~The second action was filed in Douglas County against CONMED’s landlord and other allegedly related entities (the "Douglas County Action").~~ Plaintiffs ~~in the lawsuits allege~~alleged personal injury and related claims purportedly arising from or relating to exposure to Ethylene Oxide, a chemical used to sterilize certain products. ~~CONMED is defending the claims asserted directly against it and is providing indemnification for certain other defendants based on contractual provisions.~~

~~Both actions are in their early stages. The Company's~~CONMED’s motion to dismiss ~~in the Cobb County~~ action was heard on January 10, 2022, and the Court issued a ruling on June 15, 2022 dismissing 44 of the 51 plaintiffs' claims as precluded by the exclusive workers' compensation remedy, as well as one claim from a non-employee plaintiff. ~~As to~~After discovery closed in November 2023, the plaintiffs filed a voluntary dismissal without prejudice for the remaining ~~claims that were not~~plaintiffs in the ~~subject~~case. The remaining plaintiffs have until June 2024 to refile.

The second action was filed in Douglas County against CONMED’s landlord (the "Landlord Defendants") and other allegedly related entities (the "Douglas County Action"). Plaintiff alleged the same injuries as the Cobb County Action. Discovery closed in November 2023. The Landlord Defendants filed a Motion for Summary Judgment in March of ~~the motion to dismiss, CONMED believes it has strong defenses and will vigorously defend itself and all parties it is indemnifying.~~2024. As with any litigation, there are risks, including the risk that ~~CONMED~~the Landlord defendants may not prevail with respect to the defense of the underlying claims, ~~or with respect to~~and that CONMED may not prevail in securing the adequate insurance ~~coverage for~~to cover the indemnification ~~claims. The Company is unable to estimate a range~~ of ~~possible loss at this time, and has not recorded~~ any ~~expense related to potential damages in connection with this matter because the Company does not believe any potential loss is probable.~~judgment.

CONMED submitted the foregoing claims for insurance coverage. One insurer is providing coverage for certain of the claims asserted directly against the Company. CONMED litigated two lawsuits in the United States District Court for the Northern District of New York ("the Northern District") with Federal Insurance Company (“Chubb”): one involving CONMED’s claim for coverage for the indemnification claims arising from the Cobb County Action, and the other concerning CONMED’s claim for coverage for the indemnification claims arising from the Douglas County Action. On March 10, 2022, the Court ruled in favor of CONMED with respect to coverage for the indemnification claims arising from the Cobb County

Table of Contents

Action. Chubb's motion for reconsideration was denied, and Chubb filed a notice of appeal. On August 9, 2022, CONMED won a similar ruling finding in its favor and against Chubb as to the coverage case concerning the Douglas County Action. Chubb appealed that decision as well. Chubb subsequently withdrew its appeal in connection with a settlement between the parties. Chubb disputes the amount it owes in fees incurred by the Company's attorneys defending the Douglas County action going forward. Accordingly, CONMED has commenced a third action against Chubb in the Northern District to enforce the terms of the settlement agreement, although there can be no assurance that CONMED will prevail.

~~Table of Contents~~

In addition, one of CONMED’s contract sterilizers, which is defending toxic tort claims asserted by various residents in the areas around its processing facility, has placed CONMED on notice of a claim for indemnification relating to some of those claims. CONMED ~~is reviewing~~reviewed the notice and reached out to the contract sterilizer for more information. At this time, the contract sterilizer has not ~~at this time taken any position on the notice.~~responded.

The government of Italy passed a law in late 2015 to tax medical device companies on revenue derived from sales to public hospitals. The tax is calculated and based on provincial spending over and above certain thresholds. The Italy medical device tax represents variable consideration in the form of a retroactive discount potentially owed to the customer, which is ultimately the Italian government. Since the law was enacted through September 2022, the Italian government essentially made no effort to administer or collect the tax. A lack of interpretative guidance and the complexity of the law resulted in uncertainty as to the actual amount of liability. In September 2022, the Italian government passed a further decree which, amongst other provisions, delegated administration and collection to the provincial level for the years 2015 – 2018. The ~~Italy medical device tax represents variable consideration in the form of a retroactive discount potentially owed to the customer, which is ultimately the Italian government. The~~ Company is challenging the imposition of the medical device tax in Italy, as have many other medical device companies, on the ~~ground~~grounds that the law was never implemented properly with regulations. While the Company is informed that its position is well-grounded in the law, there can be no assurance that the Company will prevail. NoThe Company has recorded reserves in accordance with the provisions of the law, although no amounts have been remitted to date.

In December 2023, the Company voluntarily informed the U.S. Department of Justice (“DOJ”) of potential issues with certain royalty payments related to design surgeons. The Company is fully cooperating with the DOJ and their review of the matter.

From time to time, we are also subject to negligence and other claims arising out of the ordinary conduct of our business, including, for example, automobile or other accidents our employees may experience within the course of their employment or otherwise and which may, on occasion, involve potentially significant personal injuries or other exposures.

We record reserves sufficient to cover probable and estimable losses associated with any such pending claims. With respect to the matters described above, except as noted related to the medical device tax in Italy, the Company is unable to estimate a range of possible loss at this time, nor does it believe any potential loss is probable, and as a result has not recorded any reserves related to the potential outcomes in connection with these matters. We do not expect that the resolution of any pending claims, investigations or reports of alleged misconduct will have a material adverse effect on our financial condition, results of operations or cash flows. There can be no assurance, however, that future claims, investigations, or ~~investigations,~~reports of alleged misconduct, or the costs associated with responding to such claims, investigations or reports of alleged misconduct, especially ~~claims and investigations~~when not covered by insurance, will not have a material adverse effect on our financial condition, results of operations or cash flows.

2219

Table of Contents


Item 2.			MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

In this Report on Form 10-Q, we make forward-looking statements about our financial condition, results of operations and business. Forward-looking statements are statements made by us concerning events that may or may not occur in the future. These statements may be made directly in this document or may be “incorporated by reference” from other documents. Such statements may be identified by the use of words such as “anticipates”, “expects”, “estimates”, “intends” and “believes” and variations thereof and other terms of similar meaning.

Forward-Looking Statements are not Guarantees of Future Performance

Forward-looking statements involve known and unknown risks, uncertainties and other factors, including those that may cause our actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include those identified under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2022~~2023 and the following, among others:

•general economic and business conditions, including, without limitation, a potential economic downturn, supply chain challenges and constraints, including the availability and cost of materials, the effects of inflation, and increased interest rates;

•compliance with and changes in regulatory requirements;

•the failure of any enterprise-wide software programs or information technology systems, or potential disruption associated with updating or implementing new software programs or information technology systems;

•the risk of an information security breach, including a cybersecurity breach;

•pandemics and health crises, and the ~~COVID-19 global pandemic,~~responses thereto by governments and hospitals, which poses risks to our business, financial condition and results of ~~operations as the pandemic and government and hospital responses to it, continue;~~operations;

•the possibility that United States or foreign regulatory and/or administrative agencies may initiate enforcement actions against us or our distributors;

•the introduction and acceptance of new products;

•the ability to advance our product lines, including challenges and uncertainties inherent in product research and development, and the uncertain impact, outcome and cost of ongoing and future clinical trials and market studies;

•competition;

•laws and government regulations;

•changes in customer preferences;

•changes in technology;

•cyclical customer purchasing patterns due to budgetary, staffing and other constraints;

•environmental compliance risks, including lack of availability of sterilization with Ethylene Oxide (“EtO”) or other compliance costs associated with the use of EtO;

•the quality of our management and business abilities and the judgment of our personnel, as well as our ability to attract, motivate and retain employees at all levels of the Company;

•the availability, terms and deployment of capital;

•current and future levels of indebtedness and capital spending;

•changes in foreign exchange and interest rates;

•the ability to evaluate, finance and integrate acquired businesses, products and companies;

•changes in business strategy;

•the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues;

•the ability to defend and enforce intellectual property, including the risks related to theft or compromise of intellectual property in connection with our international operations;

•the risk of patent, product and other litigation, as well as the cost associated with such litigation;

•trade protection measures, tariffs and other border taxes, and import or export licensing requirements; and

•weather related events which may disrupt our operations.

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations” below and “Risk Factors” and “Business” in our Annual Report on Form 10-K for the year ended December 31, ~~2022~~2023 for a further discussion of these factors. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the

Table of Contents

date hereof. We do not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect

~~Table of Contents~~

events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

Overview

Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine and lower extremities instrumentation and implants, small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. These product lines as a percentage of consolidated net sales are as follows:






		Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022		2023		2022
Orthopedic surgery	Orthopedic surgery	44	%	43	%	44	%	44	%
Orthopedic surgery
Orthopedic surgery
General surgery
General surgery
General surgery	General surgery	56	%	57	%	56	%	56	%
Consolidated net sales	Consolidated net sales	100	%	100	%	100	%	100	%
Consolidated net sales
Consolidated net sales

A significant amount of our products are used in surgical procedures with approximately~~84%~~ 85% of our revenues derived from the sale of single-use products. Our capital equipment offerings also facilitate the ongoing sale of related single-use products and accessories, thus providing us with a recurring revenue stream. We manufacture substantially all of our products in facilities located in the United States and Mexico. We market our products both domestically and internationally directly to customers and through distributors. International sales approximated ~~45% and 46%~~44% of our consolidated net sales during both the ~~six~~three months ended ~~June 30, 2023~~March 31, 2024 and ~~2022, respectively.~~2023.

Business Environment

The Company has been and continues to be impacted by the macro-economic environment and we are experiencing higher manufacturing and operating costs caused by inflationary pressures and ongoing supply chain challenges. We ~~continuously~~ work with suppliers to mitigate these impacts; however, we expect these challenges to continue through ~~2023.~~2024. This will likely impact our results of operations.

The Company has not been materially impacted by the conflicts in Ukraine and the Middle East.The Company has no direct operations in ~~either Russia or Ukraine and~~these regions with our business is limited to selling to third party distributors. Total revenues and accounts receivable associated with sales to third party distributors in these ~~countries~~regions are not material to the consolidated condensed financial ~~results, and we have fully reserved the outstanding accounts receivable from distributors in these territories which are not material.~~statements. We will continue to monitor and adjust our business strategy in ~~this region~~response to the conflicts in these regions as necessary.

During the fourth quarter of 2022, we implemented a warehouse management system to increase capacity and efficiency, however this also caused significant delays in shipping and increased costs. During the first half of 2023, we made significant progress and improvement with the performance of our warehouse management system and the shipping delays that existed at year-end 2022 were substantially reduced.~~However, there remains a risk of loss of sales and customers as a result of the shipping disruptions which occurred.~~

Critical Accounting Policies

Preparation of our financial statements requires us to make estimates and assumptions which affect the reported amounts of assets, liabilities, revenues and expenses. Note 1 to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, ~~2022~~2023 describes the significant accounting policies used in preparation of the Consolidated Financial Statements. On an ongoing basis, we evaluate the critical accounting policies used to prepare our consolidated financial statements, including, but not limited to, those related to goodwill and intangible assets, contingent consideration and our pension benefit obligation.

Table of Contents

Consolidated Results of Operations

The following table presents, as a percentage of net sales, certain categories included in our consolidated condensed statements of comprehensive income ~~(loss)~~ for the periods indicated:

Three Months Ended June 30, Six Months Ended June 30,
2023 2022 2023 2022
Net sales 100.0 % 100.0 % 100.0 % 100.0 %
Cost of sales 46.3 45.2 46.8 44.6
Gross profit 53.7 54.8 53.2 55.4
Selling and administrative expense 40.8 41.8 42.4 42.1
Research and development expense 4.3 4.1 4.3 4.3
Income from operations 8.6 8.8 6.5 9.0
Interest expense 3.1 2.1 3.3 2.1
Other expense — 40.4 — 21.6
Income (loss) before income taxes 5.5 (33.7) 3.2 (14.6)
Provision for income taxes 1.2 27.0 0.7 14.9
Net income (loss) 4.3 % (60.7) % 2.5 % (29.5) %

~~Table of Contents~~


	Three Months Ended March 31,
	2024		2023
Net sales	100.0	%	100.0	%
Cost of sales	44.9		47.4
Gross profit	55.1		52.6
Selling and administrative expense	39.5		44.0
Research and development expense	4.4		4.2
Income from operations	11.2		4.3
Interest expense	3.1		3.5

Income before income taxes	8.1		0.8
Provision for income taxes	1.8		0.2
Net income	6.3	%	0.6	%

Net Sales

The following table presents net sales by product line for the three ~~and six~~ months ended ~~June 30, 2023~~March 31, 2024 and ~~2022:~~2023:


		Three Months Ended
							% Change
		2023		2022			As Reported		Impact of Foreign Currency		Constant Currency
	Three Months Ended																																		Three Months Ended
						% Change																																							% Change
	2024																		2024							2023						As Reported						Impact of Foreign Currency						Constant Currency
Orthopedic surgery	Orthopedic surgery	$	140.8	$	120.2		17.1	%	2.7	%	19.8	%	Orthopedic surgery		$	134.9		$				$	131.2		2.8			2.8		%				0.2		%				3.0		%
General surgery	General surgery	176.9		157.0			12.6	%	1.5	%	14.1	%	General surgery		177.4			164.3					164.3			8.0			8.0		%				0.2		%				8.2		%
Net sales	Net sales	$	317.7	$	277.2		14.6	%	2.0	%	16.6	%	Net sales		$	312.3		$				$	295.5		5.7			5.7		%				0.2		%				5.9		%

Single-use products
Single-use products
Single-use products	Single-use products	$	264.8	$	230.3		14.9	%	2.0	%	16.9	%	$	264.7			$			$	249.3			6.2			6.2	%					0.1	%					6.3	%
Capital products	Capital products	52.9		46.9			12.9	%	2.2	%	15.1	%	Capital products		47.6			46.2					46.2			3.1			3.1		%				0.3		%				3.4		%
Net sales	Net sales	$	317.7	$	277.2		14.6	%	2.0	%	16.6	%	Net sales		$	312.3		$				$	295.5		5.7			5.7		%				0.2		%				5.9		%

		Six Months Ended
							% Change
		2023		2022			As Reported		Impact of Foreign Currency		Constant Currency
Orthopedic surgery		$	272.0	$	227.7		19.4	%	3.3	%	22.7	%
General surgery		341.1		291.8			16.9	%	2.0	%	18.9	%
Net sales		$	613.1	$	519.5		18.0	%	2.6	%	20.6	%

Single-use products		$	514.0	$	431.8		19.0	%	2.6	%	21.6	%
Capital products		99.1		87.7			13.0	%	2.6	%	15.6	%
Net sales		$	613.1	$	519.5		18.0	%	2.6	%	20.6	%

Net sales increased ~~14.6% and 18.0%~~5.7% in the three ~~and six~~ months ended ~~June 30, 2023, respectively,~~March 31, 2024 compared to the same ~~periods~~period a year ago primarily due to increases ~~across the majority of our~~in both orthopedic surgery and general surgery product lines, including sales from the recently acquired In2Bones and Biorez products. Further contributing to sales growth during the six months ended June 30, 2023 was the significant progress and improvement we made with the performance of our warehouse management system and significant reduction in the shipping delays that existed at year-end 2022.lines.

•Orthopedic surgery sales increased ~~17.1% and 19.4%~~2.8% in the three ~~and six~~ months ended ~~June 30, 2023, respectively, as a result of the recently acquired In2Bones~~March 31, 2024 primarily driven by growth in procedure specific and ~~Biorez products and increases in our orthopedic~~BioBrace® product offerings.

•General surgery sales increased ~~12.6% and 16.9%~~8.0% in the three ~~and six~~ months ended ~~June 30, 2023, respectively,~~March 31, 2024 on growth in our AirSeal ~~Buffalo Filter~~® and ~~other surgical~~biliary product offerings.

Cost of Sales

Cost of sales increased to ~~$147.0~~$140.3 million in the three months ended ~~June 30, 2023~~March 31, 2024 as compared to ~~$125.4~~$140.1 million in the three months ended ~~June 30, 2022 and increased to $287.1 million in the six months ended June 30, 2023 as compared to $231.7 million in the six months ended June 30, 2022.~~March 31, 2023. Gross profit margins ~~decreased 110~~increased 250 basis points to ~~53.7%~~55.1% in the three months ended ~~June 30, 2023~~March 31, 2024 as compared to ~~54.8%~~52.6% in the three months ended ~~June 30, 2022. Gross profit margins decreased 220 basis points to 53.2% in the six months ended June 30, 2023 as compared to 55.4% in the six months ended June 30, 2022.~~March 31, 2023.

~~Decreases~~The 250 basis point increase in gross profit margins ~~are driven by cost increases and inflation in raw materials, freight and other costs of production.~~during the three months ended March 31, 2024 was mainly due to favorable product mix during the three months ended March 31, 2024. In addition, during the three ~~and six~~ months ended ~~June 30,~~March 31, 2024, we wrote off $1.4 million in inventory, tooling and equipment related to the cancellation of a planned new product line

Table of Contents

and $0.2 million in severance related to the elimination of certain positions. During the three months ended March 31, 2023, we incurred costs for the amortization of inventory step-up to fair value of ~~$2.2~~$2.1 million ~~and $4.3 million, respectively,~~ related to the In2Bones acquisition, ~~compared to $0.3 million of such costs during the three and six months ended June 30, 2022. During the six months ended June 30, 2023,~~

~~Table of Contents~~

~~we also incurred~~ $1.1 million in consulting fees related to a cost improvement initiative and $1.0 million in severance related to the elimination of certain positions.

Selling and Administrative Expense

Selling and administrative expense ~~increased~~decreased to ~~$129.7~~$123.4 million in the three months ended ~~June 30, 2023~~March 31, 2024 as compared to ~~$115.8~~$130.1 million in the three months ended ~~June 30, 2022, and increased to $259.8 million in the six months ended June 30, 2023 as compared to $218.7 million in the six months ended June 30, 2022.~~March 31, 2023. Selling and administrative expense as a percentage of net sales decreased ~~a 100~~450 basis points to ~~40.8%~~39.5% in the three months ended ~~June 30, 2023~~March 31, 2024 as compared to ~~41.8%~~44.0% in the three months ended ~~June 30, 2022 and increased 30~~March 31, 2023. The 450 basis ~~points to 42.4% in the six months ended June 30, 2023 as compared to 42.1% in the six months ended June 30, 2022. The increases~~point decrease in selling and administrative expense as a percentage of net sales for the three ~~and six~~ months ended ~~June 30, 2023 were~~March 31, 2024 was primarily driven by:

•~~$1.8~~A decrease of $10.9 million in costs related to fair value adjustments to contingent consideration ($6.5 million of income in 2024 compared to $4.4 million expense in 2023), see Note 6; and ~~$6.1~~

•$4.3 million in costs related to the implementation of a new warehouse management system ~~during the three and six months ended June 30, 2023, respectively.~~in 2023. These costs mainly consisted of incremental freight, labor and travel costs as well as professional ~~fees;~~

•~~$2.1 million in costs related to the termination of distribution agreements during the three and six months ended June 30, 2023;~~

•~~$(0.6) million and $3.8 million in fair value adjustments to contingent consideration during the three and six months ended June 30, 2023, respectively; and~~

•~~$1.6 million in costs consisting of severance related to the elimination of certain positions during the six months ended June 30, 2023.~~fees.

These ~~increases~~decreases are offset by the $2.6 million in consulting fees and legal costs associated with the acquisition of In2Bones and the $0.8 million in costs related to a legal settlement during the three and six months ended June 30, 2022. In addition, we continue to experience lower ongoinghigher selling and administrative expenses ~~as a percentage of revenue as we leverage our existing selling and administrative structure.~~associated with higher sales volumes.

Research and Development Expense

Research and development expense increased to $13.6 million in the three months ended ~~June 30, 2023~~March 31, 2024 as compared to ~~$11.5~~$12.5 million in the three months ended ~~June 30, 2022, and increased to $26.1 million from $22.2 million in the six months ended June 30, 2022.~~March 31, 2023. As a percentage of net sales, research and development expense increased 20 basis points to ~~4.3%~~4.4% in the three months ended ~~June 30, 2023~~March 31, 2024 as compared to ~~4.1%~~4.2% in the three months ended ~~June 30, 2022 and remained flat at 4.3% during the six months ended June 30, 2023 as compared to the six months ended June 30, 2022.~~March 31, 2023. The ~~changes~~change in spend as a percentage of sales ~~were~~was mainly driven by additional research projects during the ~~timing of research projects.~~three months ended March 31, 2024 as compared to the same period in the prior year.

Interest Expense

Interest expense ~~increased~~decreased to ~~$10.0~~$9.6 million in the three months ended ~~June 30, 2023~~March 31, 2024 from ~~$5.9~~$10.3 million in the three months ended ~~June 30, 2022, and increased to $20.3 million in the six months ended June 30, 2023 from $10.9 million in the six months ended June 30, 2022.~~March 31, 2023. The weighted average interest rates on our borrowings increased to ~~3.09%~~3.18% in the three months ended ~~June 30, 2023~~March 31, 2024 as compared to ~~2.37%~~3.14% in the three months ended ~~June 30, 2022.~~March 31, 2023. The ~~weighted average interest rates on our borrowings increased to 3.11% in the six months ended June 30, 2023 as compared to 2.30% in the six months ended June 30, 2022. The increases~~decrease in interest expense in the three ~~and six~~ months ended ~~June 30, 2023 were primarily~~March 31, 2024 was driven by ~~the issuance of the 2.250% Notes in June 2022 as well as higher interest rates~~lower weighted average borrowings outstanding on our senior credit ~~agreement.~~facility during 2024.

~~Other Expense~~

During the three and six months ended June 30, 2022, we recorded expense of $103.1 million related to the conversion premium on the repurchase and extinguishment of 2.625% Notes; $5.5 million related to the settlement of the associated convertible notes hedge transactions and $3.4 million related to the write-off of deferred financing fees associated with the repurchase of $275.0 million of the 2.625% Notes and the pay down of $90.0 million on our term loan as further described in Note 11.

~~Table of Contents~~

Provision for Income Taxes

The Company's tax provision for interim periods is determined using an estimate of its annual effective tax rate applied to its year-to-date earnings, and also adjusting for discrete items arising in that quarter. In each quarter, the Company updates its estimate of the annual effective tax rate and if the estimated annual effective tax rate changes, the Company would make a cumulative adjustment in that quarter.

Income tax expense has been recorded at an effective tax rate of ~~21.2%~~22.5% for the three months ended ~~June 30, 2023~~March 31, 2024 compared to ~~an income tax expense at an effective tax rate of (80.0)%~~25.6% for the three months ended ~~June 30, 2022. Income tax expense has been recorded at an~~March 31, 2023. The lower effective tax rate ~~of 21.7% for the six months ended June 30, 2023 compared to (101.6)% for the six months ended June 30, 2022. The higher effective tax rates~~ for the three ~~and six~~ months ended ~~June 30, 2023 were~~March 31, 2024 was primarily the result of ~~pretax~~the higher income in ~~2023 as compared to pretax losses generated by the premium on extinguishment and change in fair value~~2024 incurring a lower percentage of ~~convertible notes hedges which were not deductible for~~ tax ~~in the same periods in the prior year.~~expense. The three months ended ~~June 30,~~March 31, 2024 included discrete income tax benefit related to acquired federal research credits which reduced the effective tax rate by 1.4% and discrete income tax expense from stock options which increased the effective tax rate by 0.4% as compared to the three months ended March 31, 2023 which included discrete income tax benefit from stock option exercises which reduced the effective tax rate by 8.4% and discrete income tax expense from other foreign related taxes which increased the effective tax rate by 2.0% as compared to three months ended June 30, 2022 which included no discrete items. The six months ended June 30, 2023 included discrete income tax benefit from stock option exercises which decreased the effective tax rate by 7.7% and discrete income tax expense from other foreign related taxes which increased the effective tax rate by 1.8% as compared to the tax benefit from stock option exercises which increased the effective tax rate by 2.2% for the six months ended June 30, 2022.2.4%. A reconciliation of the United States statutory income tax rate to our effective tax rate is included in our Annual Report on Form 10-K for the year ended December 31, ~~2022~~2023 under Note 9 to the consolidated financial statements.

Table of Contents

Non-GAAP Financial Measures

Net sales on a "constant currency" basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales.

Because non-GAAP financial measures are not standardized, it may not be possible to compare this financial measure with other companies' non-GAAP financial measures having the same or similar names. This adjusted financial measure should not be considered in isolation or as a substitute for reported net sales growth, the most directly comparable GAAP financial measure. This non-GAAP financial measure is an additional way of viewing net sales that, when viewed with our GAAP results, provides a more complete understanding of our business. The Company strongly encourages investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

Liquidity and Capital Resources

Our liquidity needs arise primarily from capital investments, working capital requirements and payments on indebtedness under the seventh amended and restated senior credit agreement. We have historically met these liquidity requirements with funds generated from operations and borrowings under our revolving credit facility. In addition, we have historically used term borrowings, including borrowings under the seventh amended and restated senior credit agreement to finance our acquisitions. We also have the ability to raise funds through the sale of stock or we may issue debt through a private placement or public offering.

Operating cash flows

Our net working capital position was ~~$262.4~~$344.3 million at ~~June 30, 2023.~~March 31, 2024. Net cash provided by operating activities was ~~$22.8~~$29.1 million in the ~~six~~three months ended ~~June 30, 2023 and $19.1~~March 31, 2024 compared to net cash used in operating activities of $3.8 million in the ~~six~~three months ended ~~June 30, 2022,~~March 31, 2023, generated on net income ~~(loss)~~ of ~~$15.6~~$19.7 million and ~~$(153.3)~~$1.8 million for the ~~six~~three months ended ~~June 30,~~March 31, 2024 and 2023, ~~and 2022,~~ respectively. Significant changes in assets and liabilities affecting operating cash flows in the ~~six~~three months ended ~~June 30, 2023~~March 31, 2024 include the following:

•~~A decrease in cash flows from accounts receivable based on the timing of sales and cash receipts;~~

•An increase in cash flows from ~~inventory~~accounts receivable as we ~~moderate our inventory levels;~~

•~~A decrease~~experienced higher sales in the fourth quarter of 2023 compared to the fourth quarter of 2022 as well as the timing of cash ~~flows from other assets as we increased our field inventory in support of increased sales;~~receipts;

•An increase in cash flows from accounts payable due to the timing of payments; and

•A decrease in cash flows from ~~other liabilities primarily resulting from income tax payments.~~accrued compensation and benefits as a result of higher incentive compensation payments in the three months ended March 31, 2024 compared to the same period a year ago.

~~Table of Contents~~

Investing cash flows

Net cash used in investing activities in the ~~six~~three months ended ~~June 30, 2023~~March 31, 2024 decreased ~~$142.2~~$2.2 million from the same period a year ago ~~primarily~~ due to capital expenditures being lower at $2.0 million in the ~~$142.6~~three months ended March 31, 2024 compared to $4.3 million ~~payment for~~in the ~~In2Bones acquisition in 2022.~~same period a year ago.

Financing cash flows

Net cash used in financing activities in the ~~six~~three months ended ~~June 30, 2023~~March 31, 2024 was ~~$14.4~~$17.0 million compared to net cash provided by financing activities of ~~$166.6~~$5.4 million during ~~2022.~~2023. Below is a summary of the significant financing activities impacting the change during the ~~six~~three months ended ~~June 30, 2023~~March 31, 2024 compared to ~~2022:~~2023:

•WeDuring the three months ended March 31, 2024, we repaid the remaining $70.0 million outstanding on the 2.625% Notes.

•During the three months ended March 31, 2024, we paid $26.9 million in contingent consideration related to the In2Bones and Biorez acquisitions.

•During the three months ended March 31, 2024, we had net ~~payments~~borrowings on our revolving line of credit of ~~$16.0~~$86.0 million, compared to ~~$140.0~~net borrowings of $9.0 million ~~during~~in the ~~six months ended June 30, 2022.~~same period a year ago.

•~~We received proceeds of $800.0 million in 2.250% Notes during~~During the ~~six~~three months ended ~~June 30, 2022.~~

•~~We paid $275.0 million in aggregate principal on the repurchase and extinguishment of the 2.625% Notes during the six months ended June 30, 2022.~~

•We paid $187.6 million to purchase hedges related to our 2.250% Notes. Partially offsetting this, were proceeds of $72.0 million from the issuance of warrants during the six months ended June 30, 2022.

•~~We paid $69.5 million to settle warrants related to the 2.625% Notes and received $86.2 million to settle the hedges related to the 2.625% Notes during the six months ended June 30, 2022.~~

•~~We paid $21.2 million in debt issuance costs related to the 2.250% Notes during the six months ended June 30, 2022.~~

•~~We had net payments on our term loan of $93.0 million during the six months ended June 30, 2022.~~

•WeMarch 31, 2024, we had net cash proceeds of ~~$15.3~~$1.1 million related to stock issued under employee plans ~~for the six months ended June 30, 2023~~ compared to ~~$9.2~~$3.4 million in the same period a year ago.

Table of Contents

Other Liquidity Matters

Our cash balances and cash flows generated from operations may be used to fund strategic investments, business acquisitions, working capital needs, research and development, common stock repurchases and payments of dividends to our shareholders. Management believes that cash flow from operations, including cash and cash equivalents on hand and available borrowing capacity under our seventh amended and restated senior credit agreement, will be adequate to meet our anticipated operating working capital requirements, debt service, funding of capital expenditures, dividend payments and common stock repurchases in the foreseeable future. In addition, management believes we could access capital markets, as necessary, to fund future business acquisitions.

The Company is also being impacted by the macro-economic environment and we are experiencing higher manufacturing and operating costs caused by inflationary pressures and ongoing supply chain challenges. We continue to monitor our spending and expenses in light of these factors. However, we may need to take further steps to reduce our costs, or to refinance our debt. See “Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, ~~2022,~~2023, for further discussion.

In February 2024, the Company repaid the remaining $70.0 million then outstanding of the 2.625% Notes through borrowings on our revolving credit facility and issued 0.1 million shares of the Company's common stock.

See Note 1110 for further information on our financing agreements and ~~outside~~outstanding debt obligations.

Our Board of Directors has authorized a $200.0 million share repurchase program. Through ~~June 30, 2023,~~March 31, 2024, we have repurchased a total of 6.1 million shares of common stock aggregating $162.6 million under this authorization and have $37.4 million remaining available for share repurchases. The repurchase program calls for shares to be purchased in the open market or in private transactions from time to time. We may suspend or discontinue the share repurchase program at any time. We

~~Table of Contents~~

have not purchased any shares of common stock under the share repurchase program during ~~2023.~~2024. We have financed the repurchases and may finance additional repurchases through operating cash flow and from available borrowings under our revolving credit facility.

New ~~accounting pronouncements~~Accounting Pronouncements

See Note 3 to the consolidated condensed financial statements for a discussion of new accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no significant changes in our primary market risk exposures or in how these exposures are managed during the ~~six~~three months ended ~~June 30, 2023.~~March 31, 2024. Reference is made to Item 7A. of our Annual Report on Form 10-K for the year ended December 31, ~~2022~~2023 for a description of Qualitative and Quantitative Disclosures About Market Risk.

Item 4. Controls and Procedures

As of the end of the period covered by this report, an evaluation was carried out by CONMED Corporation’s management, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures were effective as of the end of the period covered by this report. In addition, no change in our internal

Table of Contents

control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) occurred during the quarter ended ~~June 30, 2023~~March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

Reference is made to Item 3 of the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2022~~2023 and to Note 1514 of the Notes to Consolidated Condensed Financial Statements included in Part I of this Report for a description of certain legal matters.

Item 5. Other Information

~~On May 4, 2023, Heather Cohen,~~During the quarter ended March 31, 2024, none of the members of our Board of Directors or Executive ~~Vice President and Chief Human Resources and Legal Officer,~~Officers adopted, modified or terminated a trading ~~plan with respect to 6,500 stock appreciation rights ("SARs") granted to Ms. Cohen as equity compensation (the "Cohen Plan"). The Cohen Plan is~~arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c), under the Securities Exchange Act of ~~1934, and terminates on May 17, 2024.~~1934.

3026

Table of Contents

Item 6. Exhibits


Exhibit Index

Exhibit No.			Description of Exhibit

~~3.1~~			~~Amended and Restated Certificate of Incorporation of CONMED Corporation~~

31.1			Certification of Curt R. Hartman pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2			Certification of Todd W. Garner pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1			Certifications of Curt R. Hartman and Todd W. Garner pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS			XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH			XBRL Taxonomy Extension Schema Document

101.CAL			XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF			XBRL Taxonomy Extension Definition Linkbase Document

101.LAB			XBRL Taxonomy Extension Label Linkbase Document

101.PRE			XBRL Taxonomy Extension Presentation Linkbase Document

104			Cover Page - Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101)

3127

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on the date indicated below.


						CONMED CORPORATION



						By: /s/ Todd W. Garner
						Todd W. Garner
						Executive Vice President, Finance and
						Chief Financial Officer

						Date:
						~~July 27, 2023~~April 25, 2024

3228


	In2Bones		Biorez		Location in Financial Statements
Balance as of January 1, 2023	$	70,198	$	116,234

Changes in fair value of contingent consideration	136		3,663		Selling and administrative expense

Balance as of June 30, 2023	$	70,334	$	119,897


	Three Months Ended June 30, 2023						Three Months Ended June 30, 2022
	Basic EPS		Adjustments		Diluted EPS		Basic EPS		Adjustments		Diluted EPS
Net income (loss)	$	13,732	$	—	$	13,732	$	(168,291)	$	—	$	(168,291)

Weighted average shares outstanding	30,662		—		30,662		29,775		—		29,775

Stock compensation	—		874		874		—		—		—

Warrants	—		45		45		—		—		—

Convertible notes	—		214		214		—		—		—

	30,662		1,133		31,795		29,775		—		29,775

EPS	$	0.45			$	0.43	$	(5.65)			$	(5.65)


	Six Months Ended June 30, 2023					Six Months Ended June 30, 2022
	Basic EPS		Adjustments	Diluted EPS		Basic EPS		Adjustments	Diluted EPS
Net income (loss)	$	15,551	—	$	15,551	$	(153,316)	—	$	(153,316)

Weighted average shares outstanding	30,587		—	30,587		29,601		—	29,601

Stock compensation	—		751	751		—		—	—

Warrants	—		22	22		—		—	—

Convertible notes	—		139	139		—		—	—

	30,587		912	31,499		29,601		—	29,601

EPS	$	0.51		$	0.49	$	(5.18)		$	(5.18)